News for Healthier Living
Immune Drug Anifrolumab Linked to Lower Risk of Infection and Hospitalization for Skin Lupus
Preliminary results from an investigator-initiated single-site clinical study show that some people with chronic cutaneous lupus erythematosus -- a type of lupus that can cause permanent skin damage and hair loss -- are less likely to acquire life-threatening infections when taking the drug anifrolumab, an FDA-approved monoclonal antibody treatment for systemic lupus erythematosus.
September 2, 2026
September 7 2026September 5 2026September 4 2026September 3 2026September 2 2026September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026August 24 2026
|
|
|
|
|